These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24831980)

  • 1. A near miss for prostate cancer immunotherapy.
    Parker C
    Lancet Oncol; 2014 Jun; 15(7):669-71. PubMed ID: 24831980
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
    Taneja SS
    J Urol; 2015 Mar; 193(3):848-9. PubMed ID: 25765387
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer: mixed responses to ipilimumab.
    Killock D
    Nat Rev Urol; 2014 Jun; 11(6):305. PubMed ID: 24861332
    [No Abstract]   [Full Text] [Related]  

  • 4. Radiation therapy and immunotherapy: growing pains.
    Golden EB; Formenti SC
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):252-4. PubMed ID: 25636751
    [No Abstract]   [Full Text] [Related]  

  • 5. Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,
    Trump D
    Urol Oncol; 2016 May; 34(5):249-50. PubMed ID: 25907621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current treatment concepts for castration resistant prostate cancer].
    von Amsberg G; Stroelin P; Bokemeyer C; Steuber T
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2086-90. PubMed ID: 25268211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects for the use of ipilimumab in treating advanced prostate cancer.
    Wei XX; Fong L; Small EJ
    Expert Opin Biol Ther; 2016; 16(3):421-32. PubMed ID: 26698365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Case of Locally Advanced Castration-resistant Prostate Cancer With Remarkable Response to Nivolumab.
    Basnet A; Khullar G; Mehta R; Chittoria N
    Clin Genitourin Cancer; 2017 Oct; 15(5):e881-e884. PubMed ID: 28625691
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
    Beer TM; Kwon ED; Drake CG; Fizazi K; Logothetis C; Gravis G; Ganju V; Polikoff J; Saad F; Humanski P; Piulats JM; Gonzalez Mella P; Ng SS; Jaeger D; Parnis FX; Franke FA; Puente J; Carvajal R; Sengeløv L; McHenry MB; Varma A; van den Eertwegh AJ; Gerritsen W
    J Clin Oncol; 2017 Jan; 35(1):40-47. PubMed ID: 28034081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabazitaxel for the therapy of metastatic castration-resistant prostate cancer in the aftermath of the CHAARTED trial.
    Pal SK; Sonpavde G
    BJU Int; 2015 Dec; 116(6):839-40. PubMed ID: 26542327
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
    Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.
    Saad F; Miller K
    Urology; 2015 May; 85(5):976-986. PubMed ID: 25709051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
    Dreicer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapy in prostate cancer.
    Sobol I; Thompson RH; Dong H; Krco C; Kwon ED
    Curr Urol Rep; 2015 Jun; 16(6):34. PubMed ID: 25894495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?
    Taplin ME; Balk SP
    JAMA Oncol; 2015 Aug; 1(5):577-9. PubMed ID: 26181796
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial Comment to High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
    van Soest RJ
    Int J Urol; 2015 Sep; 22(9):834. PubMed ID: 26104026
    [No Abstract]   [Full Text] [Related]  

  • 17. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ASCO 2016: Confirmation of respective roles of docetaxel and cabazitaxel in prostate cancer patients].
    Penel N
    Bull Cancer; 2016 Sep; 103(9):714-6. PubMed ID: 27597565
    [No Abstract]   [Full Text] [Related]  

  • 19. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 20. [Docetaxel and prostate cancer: Early but not too early].
    Penel N; Ryckewaert T; Amela EY
    Bull Cancer; 2015 Sep; 102(9):710-2. PubMed ID: 26235414
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.